Verastem Inc.

1.08-0.0100-0.92%Vol 476 8291Y Perf -80.29%
Nov 11th, 2019 16:00
BID1.07 ASK1.10
Open1.10 Previous Close1.09
Pre-Market1.10 After-Market1.08
 0.01 0.92%  - -%
Target Price
2.75 
Analyst Rating
Moderate Buy 1.67
Potential %
154.63 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/100 
Income Ranking
 —    -
Market Cap (M)80 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
0.86 
Earnings Date
29th Oct 2019

Today's Price Range

1.071.10

52W Range

1.045.71

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.92%
1 Month
-0.92%
3 Months
-17.56%
6 Months
-20.59%
1 Year
-80.29%
3 Years
-13.60%
5 Years
-88.47%
10 Years
-

TickerPriceChg.Chg.%
VSTM1.08-0.0100-0.92
AAPL262.202.06000.79
GOOG1 299.19-12.1800-0.93
MSFT146.110.15000.10
XOM70.34-0.4300-0.61
WFC54.05-0.0500-0.09
JNJ131.98-1.0200-0.77
FB189.61-1.2300-0.64
GE11.35-0.1700-1.48
JPM129.92-0.4600-0.35
Earnings HistoryEstimateReportedSurprise %
Q03 2019-0.42-0.3516.67
Q02 2019-0.49-0.52-6.12
Q01 2019-0.46-0.51-10.87
Q04 2018-0.54-0.3731.48
Q03 2018-0.43-0.2932.56
Q02 2018-0.35-0.3014.29
Q01 2018-0.41-0.410.00
Q04 2017-0.38-0.43-13.16
Earnings Per EndEstimateRevision %Trend
12/2019 QR-0.3337.74Positive
12/2019 FY-1.859.31Positive
3/2020 QR-0.2932.56Positive
12/2020 FY-1.2234.05Positive
Next Report Date-
Estimated EPS Next Report-0.42
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume476 829
Shares Outstanding (K)74 350
Trades Count992
Dollar Volume503 084
Avg. Volume1 898 473
Avg. Weekly Volume743 103
Avg. Monthly Volume880 421
Avg. Quarterly Volume806 500
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (25.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Buy
1.67
Strong Buy
1.50
Strong Buy
1.50

Verastem Inc.

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

CEO: Robert Forrester

Teplephone: +1 781 292-4200

Address: 117 Kendrick Street, Needham 02494, MA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

43%57%

Bearish Bullish

65%35%

Bearish Bullish

58%42%

News

Stocktwits